(Q39692801)

14 September 2017

title

Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment (English)

1 reference

14 September 2017

1 reference

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Frank Bridoux

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Nianhang Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Stephane Moreau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Bertrand Arnulf

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Eric Moumas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Julie Abraham

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Estelle Desport

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Jean Paul Fermand

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

10 June 2016

1 reference

Cancer Chemotherapy and Pharmacology

14 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

173-182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-016-3068-9

8 June 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Diagnosis of monoclonal gammopathy of renal significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Validity of creatinine clearance estimates in the assessment of renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Optimizing the treatment of patients with multiple myeloma and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Renal Failure in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-3068-9

10.1007/S00280-016-3068-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27286995%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference